Bioequivalency Study Comparing Hospira's Generic Iron Sucrose Injection to Venofer
The primary objective of this study is to assess the bioequivalence of the test product Hospira Iron Sucrose 20 mg/mL (Hospira, Inc.) to the reference product Venofer® 20 mg/mL following intravenous administration to healthy subjects.
|Study Design:||Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Randomized, Open-Label, Single-Dose, Parallel-Design, Bioequivalence Study of Hospira Iron Sucrose Injection Compared to Venofer Injection USP in Healthy Subjects.|
- Bioequivalence [ Time Frame: PK sampling at various times ] [ Designated as safety issue: No ]
|Study Start Date:||June 2008|
|Primary Completion Date:||July 2008 (Final data collection date for primary outcome measure)|
Hospira Iron Sucrose
Drug: Iron Sucrose
Iron sucrose 20 mg/mL
Active Comparator: 2
Drug: Iron Sucrose
Venofer 20 mg/mL
Iron is essential to the synthesis of hemoglobin (Hb) to maintain oxygen transport and to the function and formation of other physiologically important heme and nonheme compounds. Iron deficiency may be caused by blood loss during dialysis, increased erythropoiesis following administration of epoetin, and insufficient absorption of iron from the gastro-intestinal tract. Most dialysis patients require intravenous iron supplementation to replenish iron stores.
Iron sucrose is used to replenish body iron stores in patients with iron deficiency on chronic hemodialysis and receiving erythropoietin. In these patients iron deficiency is caused by blood loss during dialysis procedure, increased erythropoiesis, and insufficient absorption of iron from the gastrointestinal tract. Most hemodialysis patients require intravenous iron to maintain sufficient iron stores to achieve and maintain a hemoglobin level of 11-12 g/dL.
Subjects who fulfill the inclusion/exclusion criteria after screening will be randomized to receive 100 mg of iron sucrose as either Hospira Iron Sucrose or Venofer®.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00719459
|United States, Missouri|
|Bio-Kinetic Clinical Applications|
|Springfield, Missouri, United States, 65802|